Tushar Pandey on Managing Thrombotic Thrombocytopenic Purpura
Tushar Pandey, Editorial Board Member at Journal of Cancer Chemotherapy, shared on LinkedIn:
”Managing Thrombotic Thrombocytopenic Purpura (TTP):
Where Speed, Systems, and Specialized Expertise Save Lives
The patient presented in a critically ill state with:
- Altered sensorium
- Generalized seizures
- Jaundice
Recognizing the severity, a rapid and comprehensive clinical, radiological, and laboratory evaluation was initiated within hours of presentation.
This enabled prompt diagnosis of Thrombotic Thrombocytopenic Purpura (TTP), a life-threatening hematological emergency.
What made the difference
- Immediate initiation of therapeutic plasma exchange (PLEX)
- High-dose immunosuppression
- Early integration of immunotherapy
- Continuous neurological and biochemical monitoring
- ICU-based, hematology-led decision-making
This was not reactive medicine.
This was planned, systematic execution by a world-class hematology team.
Multidisciplinary Excellence
Successful TTP management is never a single-department effort. I acknowledge the outstanding active participation of:
- Nephrology
- Neurology
- Critical Care and Transfusion teams, providing round-the-clock support
All teams worked in perfect synchrony from the first hour.
Outcome
Despite a high-risk and stormy course, the patient improved steadily. Platelet counts recovered, hemolysis resolved, neurological status stabilized, and she was discharged home safely.
What this case represents
World-class hematology emergency care
Expertise in ICU-level hematological crises
Early diagnosis plus early treatment equals survival
International-standard Hematology, Hemato-Oncology, and BMT care in Haldwani
As Head of Hematology, Hemato-Oncology, and BMT at Raghav Institute of Hematology, Hemato-Oncology and BMT, Haldwani, I can confidently say this case reinforces one truth:
When expertise leads early, lives are saved.”
Stay updated with Hemostasis Today.
-
Mar 13, 2026, 21:19New Canadian Insights on Switching to Longer-Acting Therapy for Hemophilia A – WFH
-
Mar 13, 2026, 21:01Leonardo Roever: Brain Age as a Biomarker of Neuroplasticity and Motor Recovery After Stroke
-
Mar 13, 2026, 20:50William Tembo: Understanding Stroke Through Landmark Clinical Trials
-
Mar 13, 2026, 20:35Jessica Garcia: New Evidence on Thrombin Generation Patterns in Children with Hemophilia A
-
Mar 13, 2026, 20:11Christoph B. Olivier: New Research from Marius Wessinger on Predicting Therapy Success After Pulmonary Embolism
-
Mar 13, 2026, 19:53Wolfgang Miesbach Announces the New English Edition of “Gene Therapy Concepts in the Treatment of Haemophilia”
-
Mar 13, 2026, 17:21Emmanuel J Favaloro: Acquired Hemostasis Disorders Featured in New Issue of Seminars in Thrombosis and Hemostasis
-
Mar 13, 2026, 17:17Paolo Zamboni: New Insights from Australia on Jugular and Azygous Vein Chronic Obstruction
-
Mar 13, 2026, 17:06Srishti Goyal: Can Thalassemia Major Be Prevented?